Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Regeneron Pharmaceuticals (NQ: REGN )

744.50 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna outperforming expectations in myasthenia gravis, offering less frequent... 
Via Benzinga
Why Is Regeneron Pharmaceuticals Stock Trading Lower On Tuesday?
Regeneron filed an appeal after a court's decision, which was issued under seal. 
Via Benzinga
This BP Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday
Via Benzinga
Tesla Leads S&P 500 Index, While Biotech Giant Tumbles On Court Ruling
The EV giant, once a big S&P 500 laggard in 2024, is now up for the year. 
Via Investor's Business Daily
Topics Stocks
Exposures US Equities
Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea
Eylea is one of Regeneron's biggest moneymakers, and Amgen is looking to knock it off. 
Via Investor's Business Daily
Smart Money Is Betting Big In REGN Options
Via Benzinga
Competitor Analysis: Evaluating Regeneron Pharmaceuticals And Competitors In Biotechnology Industry
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
Via Benzinga
Dupixent® (dupilumab) Recommended for EU Approval by the CHMP to Treat Eosinophilic Esophagitis (EoE) in Children as Young as 1 Year Old
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Time To Invest And Or Trade In Bio-Tech Stocks?
Biotechnology stocks and biotech exchange-traded funds ETFs once played a significant role in growth equity rallies, but today it seems like those days are in the past. Will an interest rate cut help... 
Via Talk Markets
Topics ETFs
Beyond The Numbers: 20 Analysts Discuss Regeneron Pharmaceuticals Stock
Via Benzinga
Evaluating Regeneron Pharmaceuticals Against Peers In Biotechnology Industry
Via Benzinga
What Analysts Are Saying About Regeneron Pharmaceuticals Stock
Via Benzinga
Biotech Breakout: Stocks for Your Watchlist
The iShares Biotechnology ETF (IBB) has turned $140 resistance into support, positioning the overall sector for a potential breakout above $150. 
Via MarketBeat
Topics ETFs
Sanofi, Regeneron Drug Dupixent Shows Successful Treatment Of Patients With Inflammatory Skin Disease
Regeneron and Sanofi's Dupixent achieves positive Phase 3 results for chronic spontaneous urticaria, meeting key endpoints. 
Via Benzinga
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits
MAIA Biotechnology's Phase 2 Study Of THIO In Non-Small Cell Lung Cancer Shows Positive Interim Survival Benefits 
Via News Direct
EYLEA HD® (aflibercept) Injection 8 mg Data at EURETINA Reinforce Long-term Durability, Sustained Fluid Control and Safety Profile
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Prediction: These 2 Companies Will Split Their Stocks by 2027
Eli Lilly and Regeneron Pharmaceuticals are good stock-split candidates thanks to years of successes. 
Via The Motley Fool
Dupixent® (dupilumab) Phase 3 Trial Confirms Significant Improvements in Itch and Hives for Patients with Chronic Spontaneous Urticaria (CSU)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve Significant Improvements in Disease Remission and Symptoms in Bullous Pemphigoid (BP) Positive Pivotal Trial
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Prediction: These 2 Cathie Wood Stocks Could Crush the Market Through 2030
These stocks have generally delivered competitive returns. 
Via The Motley Fool
Biotech And Life Science Sector Update Summer Of 2024
It’s the slowest week of the year, we are at the market top and most earnings reports are good. 
Via Talk Markets
Ordspono™ (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
Latest Dupixent® (dupilumab) and Itepekimab Data at ERS Highlight Scientific Innovation and Leadership in Respiratory Diseases
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
10 Bagger Stocks: Can You Find One?
Finding 10 baggers is not easy, but it’s a worthwhile pursuit for long-term investors. 
Via Talk Markets
Regeneron Faces Setback With FDA Rejection Of Blood-Cancer Treatment
Regeneron Pharmaceuticals Inc. has received a setback as the Food and Drug Administration has declined its application for a blood cancer treatment. 
Via Benzinga
Exposures Product Safety
Regeneron Provides Update on Biologics License Application for Linvoseltamab
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
42 43 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS